离心式磁悬浮连续流式心脏泵的研究进展

郭晨; 李敏; 吕永会; 张明卜; 王志禄

doi:10.13201/j.issn.1001-1439.2019.04.002

离心式磁悬浮连续流式心脏泵的研究进展

- 兰州大学第一医院心血管内科(兰州, 730000)

详细信息

通讯作者: 王志禄,E-mail:wangzhl@lzu.edu.cn

中图分类号: 541542.6

收稿日期: 2018-08-23

Advance in magnetically levitated centrifugal continuous-flow cardiac pump

- Department of Cardiology, The First Hospital of Lanzhou University, Lanzhou 730000, China

More Information

Corresponding author: WANG Zhilu, E-mail: wangzhl@lzu.edu.cn

Received Date: 23 August 2018

摘要

摘要: 连续流式左心室辅助装置可改善终末期心力衰竭患者的存活、功能状态和生活质量，但也伴随着出血、感染、神经系统并发症和主要由泵血栓所致泵故障风险的增加，极大限制了设备的适用性和持久性。第3代左心室辅助装置的新成员——离心式磁悬浮连续流式心脏泵的开发和使用，不仅可进一步提高心力衰竭患者的存活率和生活质量，还可明显避免泵血栓及其他血液相容性不良事件。本文旨在对新型离心式磁悬浮心脏泵的临床进展及面临的挑战予以综述。
- 磁悬浮 /
- 左心室辅助装置 /
- 人工心脏泵 /
- 终末期心力衰竭
Abstract: Continuous-flow left ventricular assist devices were capable of providing meaningful increases in survival, functional capacity, and quality of life in patients with advanced heart failure, which associated with increased risk of hemorrhage, infection, neurological complication and pump malfunction mainly caused by pump thrombosis, seriously limited the applicability and durability of the devices.The new member of the third generation left ventricular assist devices-magnetically levitated centrifugal continuous-flow cardiac pump, which engineering and application not only further improved survival and quality of life in heart failure patients, but also obviously avoided pump thrombosis and other hemocompatibility-related clinical adverse events.This article focus on the latest advances of the new magnetically levitated centrifugal continuous-flow cardiac pump and the challenges that remain.
- magnetic levitation /
- left ventricular assist device /
- artificial cardiac pump /
- advanced heart failure

HTML全文

参考文献(21)

[1]	贾晨平.心力衰竭药物治疗新进展[J].临床心血管病杂志, 2017, 33(6):601-604.
[2]	卢永昕.如何应用循证医学为基础的新指南优化心力衰竭的治疗?[J].临床心血管病杂志, 2018, 34(2):105-107.
[3]	Miller LW, Guglin M.Patient selection for ventricular assist devices:a moving target[J].J Am Coll Cardiol, 2013, 61(12):1209-1221.
[4]	刘英明, 杨晔.慢性心力衰竭器械治疗进展[J].临床心血管病杂志, 2017, 33(10):1018-1022.
[5]	Pinney SP, Anyanwu AC, Lala A, et al.Left ventricular assist devices for lifelong support[J].J Am Coll Cardiol, 2017, 69(23):2845-2861.
[6]	Roever L, Resende ES, Mehra MR.Vulnerable brain and ventricular assist devices[J].Stroke, 2016, 47(11):2677-2678.
[7]	Schmitto JD, Hanke JS, Rojas SV, et al.First implantation in man of a new magnetically levitated left ventricular assist device (HeartMate Ⅲ)[J].J Heart Lung Transplant, 2015, 34(6):858-860.
[8]	Netuka I, Sood P, Pya Y, et al.Fully magnetically levitated left ventricular assist system for treating advanced HF:a multicenter study[J].J Am Coll Cardiol, 2015, 66(23):2579-2589.
[9]	Kassi M, Hannawi B, Trachtenberg B.Recent advances in heart failure[J].Curr Opin Cardiol, 2018, 33(2):249-256.
[10]	Mehra MR, Naka Y, Uriel N, et al.A fully magnetically levitated circulatory pump for advanced heart failure[J].N Engl J Med, 2017, 376(5):440-450.
[11]	Heatley G, Sood P, Goldstein D, et al.Clinical trial design and rationale of the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3(MOMENTUM 3) investigational device exemption clinical study protocol[J].J Heart Lung Transplant, 2016, 35(4):528-536.[CM(80mm]
[12]	Netuka I, Kvasniĉka T, Kvasniĉka J, et al.Evaluation of von Willebrand factor with a fully agnetically levitated centrifugal continuous-flow left ventricular assist device in advanced heart failure[J].J Heart Lung Transplant, 2016, 35(7):860-867.
[13]	Bourque K, Cotter C, Dague C, et al.Design rationale and pre-clinical evaluation of the HeartMate 3 left ventricular assist system for hemocompatibility[J].ASAIO J, 2016, 62(4):375-383.
[14]	Pagani FD.Adverse event burden and mechanical circulatory support:looking toward the future[J].J Thorac Cardiovasc Surg, 2015, 151(1):10-12.
[15]	Krabatsch T, Netuka I, Schmitto JD, et al.Heartmate 3 fully magnetically levitated left ventricular assist device for the treatment of advanced heart failure-1 year results from the Ce mark trial[J].J Cardiothorac Surg, 2017, 12(1):23-23.
[16]	Schmitto JD, Pya Y, Zimpfer D, et al.Long-term evaluation of a fully magnetically levitated circulatory support device for advanced heart failure-two-year results from the HeartMate 3?CE Mark Study[J].Eur J Heart Fail, 2018, doi:10.1002/ejhf.1284.
[17]	Mehra MR.The burden of haemocompatibility with left ventricular assist systems:a complex weave[J].Eur Heart J, 2017.doi:10.1093/eurheartj/ehx036.
[18]	Uriel N, Colombo PC, Cleveland JC, et al.Hemocompatibility-related outcomes in the MOMENTUM 3 trial at 6 months:a randomized controlled study of a fully magnetically levitated pump in advanced heart failure[J].Circulation, 2017, 135(21):2003-2012.
[19]	Mehra MR, Goldstein DJ, Uriel N, et al.Two-year outcomes with a magnetically levitated cardiac pump in heart failure[J].N Engl J Med, 2018, 378(15):1386-1395.
[20]	Netuka I, Ivák P, Tu?anová Z, et al.Evaluation of low-intensity anti-coagulation with a fully magnetically levitated centrifugal-flow circulatory pump-the MAGENTUM 1 study[J].J Heart Lung Transplant, 2018, 37(5):579-586.
[21]	Mehra MR, Salerno C, Cleveland JC, et al.Health care resource use and cost implications in the MOMENTUM 3 Long-Term Outcome Study:A Randomized Controlled Trial of a magnetically levitated cardiac pump in advanced heart failure[J].Circulation, 2018.doi:10.1161/CIRCULATIONAHA.118.035722.